Zhang XJ, Lou J. Hemorrhagic cystitis in gastric cancer after nanoparticle albumin-bound paclitaxel: A case report. World J Gastrointest Oncol 2024; 16(3): 1084-1090 [PMID: 38577472 DOI: 10.4251/wjgo.v16.i3.1084]
Corresponding Author of This Article
Jian Lou, MM, Chief Physician, Department of Cancer Center, The Fifth Affiliated Hospital of Wenzhou Medical University, No. 289 Kuocang Road, Liandu District, Lishui 323000, Zhejiang Province, China. 19994454@qq.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 1084-1090 Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.1084
Hemorrhagic cystitis in gastric cancer after nanoparticle albumin-bound paclitaxel: A case report
Xin-Jie Zhang, Jian Lou
Xin-Jie Zhang, Jian Lou, Department of Cancer Center, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, Zhejiang Province, China
Author contributions: Zhang XJ collected data and drafted the manuscript; Lou J revised and finalized the manuscript; all authors have read and approved the final manuscript.
Informed consent statement: Written informed consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian Lou, MM, Chief Physician, Department of Cancer Center, The Fifth Affiliated Hospital of Wenzhou Medical University, No. 289 Kuocang Road, Liandu District, Lishui 323000, Zhejiang Province, China. 19994454@qq.com
Received: December 24, 2023 Peer-review started: December 24, 2023 First decision: January 10, 2024 Revised: January 18, 2024 Accepted: January 27, 2024 Article in press: January 27, 2024 Published online: March 15, 2024 Processing time: 78 Days and 18.6 Hours
Abstract
BACKGROUND
The advanced first-line regimen for advanced gastric cancer is based on a combination of fluoropyrimidine and platinum and/or paclitaxel (PTX), forming a two- or three-drug regimen. Compared to conventional PTX, nanoparticle albumin-bound PTX (Nab-PTX) has better therapeutic effects and fewer adverse effects reported in studies. Nab-PTX is a great option for patients presenting with advanced gastric cancer. Herein, we highlight an adverse event (hemorrhagic cystitis) of Nab-PTX in advanced gastric cancer.
CASE SUMMARY
A 55-year-old male was diagnosed with lymph node metastasis after a laparoscopic-assisted radical gastrectomy for gastric cancer that was treated by Nab-PTX and S-1 (AS). On the 15th day after treatment with AS, he was diagnosed with hemorrhagic cystitis.
CONCLUSION
Physicians should be aware that hemorrhagic cystitis is a potential adverse event associated with Nab-PTX treatment.
Core Tip: Chemotherapy is an important treatment method for advanced gastric cancer. Up to now, nanoparticle albumin-bound paclitaxel (Nab-PTX) has shown promising responses in advanced gastric cancer. We aim to draw attention to a rarely treatment-related adverse event after Nab-PTX.
